vs
Side-by-side financial comparison of Clarus Corp (CLAR) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $65.4M, roughly 1.3× Clarus Corp). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -8.4%). Clarus Corp produced more free cash flow last quarter ($11.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -2.9%).
Clarus Corp is a global designer, manufacturer, and distributor of high-performance outdoor recreation, climbing, camping, and lifestyle products. It manages a portfolio of leading consumer brands, serving outdoor enthusiasts, professional athletes, and retail partners across North America, Europe, and the Asia-Pacific region, with a focus on innovative, durable gear for active lifestyles.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CLAR vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $65.4M | $86.8M |
| Net Profit | $-31.3M | — |
| Gross Margin | 27.7% | 67.4% |
| Operating Margin | -59.6% | -84.7% |
| Net Margin | -47.8% | — |
| Revenue YoY | -8.4% | 17.7% |
| Net Profit YoY | 52.3% | — |
| EPS (diluted) | $-0.81 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $65.4M | $86.8M | ||
| Q3 25 | $69.3M | $67.5M | ||
| Q2 25 | $55.2M | $60.0M | ||
| Q1 25 | $60.4M | $49.3M | ||
| Q4 24 | $71.4M | $73.7M | ||
| Q3 24 | $67.1M | $58.6M | ||
| Q2 24 | $56.5M | $31.1M | ||
| Q1 24 | $69.3M | $715.0K |
| Q4 25 | $-31.3M | — | ||
| Q3 25 | $-1.6M | $-91.3M | ||
| Q2 25 | $-8.4M | $-111.7M | ||
| Q1 25 | $-5.2M | $-116.2M | ||
| Q4 24 | $-65.5M | — | ||
| Q3 24 | $-3.2M | $-83.5M | ||
| Q2 24 | $-5.5M | $-97.1M | ||
| Q1 24 | $21.9M | $-113.0M |
| Q4 25 | 27.7% | 67.4% | ||
| Q3 25 | 35.1% | 43.0% | ||
| Q2 25 | 35.6% | 5.5% | ||
| Q1 25 | 34.4% | -0.8% | ||
| Q4 24 | 33.4% | 68.7% | ||
| Q3 24 | 35.0% | 46.2% | ||
| Q2 24 | 36.1% | -0.8% | ||
| Q1 24 | 35.9% | — |
| Q4 25 | -59.6% | -84.7% | ||
| Q3 25 | -4.4% | -140.7% | ||
| Q2 25 | -19.7% | -189.8% | ||
| Q1 25 | -11.2% | -245.8% | ||
| Q4 24 | -70.2% | -117.5% | ||
| Q3 24 | -8.0% | -152.1% | ||
| Q2 24 | -14.4% | -327.6% | ||
| Q1 24 | -9.8% | -16464.6% |
| Q4 25 | -47.8% | — | ||
| Q3 25 | -2.3% | -135.3% | ||
| Q2 25 | -15.3% | -186.2% | ||
| Q1 25 | -8.7% | -235.5% | ||
| Q4 24 | -91.8% | — | ||
| Q3 24 | -4.7% | -142.7% | ||
| Q2 24 | -9.7% | -312.2% | ||
| Q1 24 | 31.6% | -15800.8% |
| Q4 25 | $-0.81 | — | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $-0.22 | $-0.33 | ||
| Q1 25 | $-0.14 | $-0.36 | ||
| Q4 24 | $-1.72 | $-0.24 | ||
| Q3 24 | $-0.08 | $-0.28 | ||
| Q2 24 | $-0.14 | $-0.34 | ||
| Q1 24 | $0.57 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.7M | $297.0M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $196.4M | $698.6M |
| Total Assets | $249.0M | $913.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.7M | $297.0M | ||
| Q3 25 | $29.5M | $300.8M | ||
| Q2 25 | $28.5M | $301.2M | ||
| Q1 25 | $41.3M | $359.7M | ||
| Q4 24 | $45.4M | $323.8M | ||
| Q3 24 | $36.4M | $397.5M | ||
| Q2 24 | $46.2M | $412.5M | ||
| Q1 24 | $47.5M | $356.2M |
| Q4 25 | $0 | — | ||
| Q3 25 | $2.0M | — | ||
| Q2 25 | $1.9M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $1.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $37.0K | — |
| Q4 25 | $196.4M | $698.6M | ||
| Q3 25 | $225.8M | $702.3M | ||
| Q2 25 | $225.1M | $698.5M | ||
| Q1 25 | $229.3M | $767.9M | ||
| Q4 24 | $233.1M | $710.4M | ||
| Q3 24 | $308.5M | $773.5M | ||
| Q2 24 | $307.3M | $768.5M | ||
| Q1 24 | $310.4M | $680.0M |
| Q4 25 | $249.0M | $913.2M | ||
| Q3 25 | $283.1M | $904.9M | ||
| Q2 25 | $286.5M | $907.4M | ||
| Q1 25 | $292.8M | $966.7M | ||
| Q4 24 | $294.1M | $910.4M | ||
| Q3 24 | $375.3M | $991.1M | ||
| Q2 24 | $369.4M | $964.3M | ||
| Q1 24 | $377.0M | $869.8M |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.5M | $-52.6M |
| Free Cash FlowOCF − Capex | $11.6M | $-61.9M |
| FCF MarginFCF / Revenue | 17.7% | -71.3% |
| Capex IntensityCapex / Revenue | 1.4% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.9M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.5M | $-52.6M | ||
| Q3 25 | $-5.7M | $-78.7M | ||
| Q2 25 | $-9.4M | $-67.4M | ||
| Q1 25 | $-2.1M | $-103.7M | ||
| Q4 24 | $16.6M | $-73.3M | ||
| Q3 24 | $-8.3M | $-59.0M | ||
| Q2 24 | $834.0K | $-98.4M | ||
| Q1 24 | $-16.4M | $-122.3M |
| Q4 25 | $11.6M | $-61.9M | ||
| Q3 25 | $-7.0M | $-89.5M | ||
| Q2 25 | $-11.3M | $-74.9M | ||
| Q1 25 | $-3.3M | $-109.9M | ||
| Q4 24 | $14.4M | $-77.5M | ||
| Q3 24 | $-9.4M | $-61.3M | ||
| Q2 24 | $-744.0K | $-98.9M | ||
| Q1 24 | $-18.3M | $-126.5M |
| Q4 25 | 17.7% | -71.3% | ||
| Q3 25 | -10.0% | -132.7% | ||
| Q2 25 | -20.4% | -124.9% | ||
| Q1 25 | -5.4% | -222.8% | ||
| Q4 24 | 20.1% | -105.1% | ||
| Q3 24 | -14.0% | -104.6% | ||
| Q2 24 | -1.3% | -317.9% | ||
| Q1 24 | -26.3% | -17685.3% |
| Q4 25 | 1.4% | 10.7% | ||
| Q3 25 | 1.8% | 16.1% | ||
| Q2 25 | 3.4% | 12.4% | ||
| Q1 25 | 2.0% | 12.6% | ||
| Q4 24 | 3.1% | 5.7% | ||
| Q3 24 | 1.6% | 3.9% | ||
| Q2 24 | 2.8% | 1.4% | ||
| Q1 24 | 2.7% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLAR
| Other | $37.1M | 57% |
| Outdoor Segment | $25.3M | 39% |
| Adventure Segment | $3.0M | 5% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
